Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know.

Schreiner, Philipp; Mueller, Nicolas J; Fehr, Jan; Maillard, Michel H; Brand, Stephan; Michetti, Pierre; Schoepfer, Alain; Restellini, Sophie; Vulliemoz, Marianne; Vavricka, Stephan R; Juillerat, Pascal; Rogler, Gerhard; Biedermann, Luc (2020). Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know. (In Press). Journal of Crohn's & colitis Oxford University Press 10.1093/ecco-jcc/jjaa132

Preview

Text jjaa132.pdf - Published Version Available under License Publisher holds Copyright. Download (319kB) | Preview

Primary Varicella Zoster virus (VZV) infection results in varicella (chickenpox) while its reactivation results in herpes zoster (HZ; shingles). Patients with Inflammatory Bowel Disease (IBD) are susceptible to complications of primary VZV infection and have an increased risk of HZ. Concerns of VZV and HZ infection in the IBD population has been highlighted by the emergence of JAK-inhibitors and their safety profile in this patient population such as tofacitinib for the treatment of ulcerative colitis (UC). The current pipeline of emerging therapies include novel molecules targeting multiple pathways including JAK/signal transducer and cytokine signalling pathways such as JAK/STAT. Hence VZV and HZ will be increasingly relevant for gastroenterologists treating IBD patients in light of these emerging therapies.

Interest & Impact

Downloads

2 since deposited on 22 Dec 2020
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item